CN111925360B - 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 - Google Patents
用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Download PDFInfo
- Publication number
- CN111925360B CN111925360B CN202010607608.6A CN202010607608A CN111925360B CN 111925360 B CN111925360 B CN 111925360B CN 202010607608 A CN202010607608 A CN 202010607608A CN 111925360 B CN111925360 B CN 111925360B
- Authority
- CN
- China
- Prior art keywords
- compound
- pyrrolidine
- pharmaceutically acceptable
- tert
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 318
- 238000011282 treatment Methods 0.000 title abstract description 16
- 208000015114 central nervous system disease Diseases 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 200
- 150000003839 salts Chemical class 0.000 claims abstract description 95
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 47
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 40
- 230000000926 neurological effect Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 126
- 229910052736 halogen Inorganic materials 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 208000028017 Psychotic disease Diseases 0.000 claims description 24
- 201000000980 schizophrenia Diseases 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 208000024714 major depressive disease Diseases 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 208000020925 Bipolar disease Diseases 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 206010026749 Mania Diseases 0.000 claims description 8
- 208000019906 panic disease Diseases 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 181
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 126
- 201000006417 multiple sclerosis Diseases 0.000 description 110
- 238000005481 NMR spectroscopy Methods 0.000 description 105
- 239000000243 solution Substances 0.000 description 96
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 95
- 235000002639 sodium chloride Nutrition 0.000 description 76
- 235000019439 ethyl acetate Nutrition 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 150000003840 hydrochlorides Chemical class 0.000 description 69
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 239000012043 crude product Substances 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 52
- -1 polymethylene group Polymers 0.000 description 48
- 239000003921 oil Substances 0.000 description 45
- 235000019198 oils Nutrition 0.000 description 45
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 42
- YDBPZCVWPFMBDH-QMMMGPOBSA-N tert-butyl (2s)-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C=O YDBPZCVWPFMBDH-QMMMGPOBSA-N 0.000 description 38
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 33
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 208000035475 disorder Diseases 0.000 description 29
- 239000002904 solvent Substances 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 28
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 27
- 239000012230 colorless oil Substances 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 239000003208 petroleum Substances 0.000 description 26
- 239000012071 phase Substances 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- 238000002953 preparative HPLC Methods 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 208000019901 Anxiety disease Diseases 0.000 description 19
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- YDBPZCVWPFMBDH-MRVPVSSYSA-N tert-butyl (2r)-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C=O YDBPZCVWPFMBDH-MRVPVSSYSA-N 0.000 description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- 229940124597 therapeutic agent Drugs 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000012267 brine Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 208000020401 Depressive disease Diseases 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 229910052740 iodine Inorganic materials 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- BRHMPAKAVCYAIB-RYUDHWBXSA-N (2S)-2-[(1S)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]pyrrolidine Chemical compound FC1=CC=C2[C@H](OCC2=C1)[C@@H]1CCCN1 BRHMPAKAVCYAIB-RYUDHWBXSA-N 0.000 description 13
- WCHMYCOJRHCHAK-UHFFFAOYSA-N 2-(2-bromo-5-fluorophenyl)ethanol Chemical compound OCCC1=CC(F)=CC=C1Br WCHMYCOJRHCHAK-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 230000008448 thought Effects 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 10
- 230000006399 behavior Effects 0.000 description 10
- 208000010877 cognitive disease Diseases 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 150000001923 cyclic compounds Chemical class 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- BEJLHUZAVNPBAT-WCQYABFASA-N (2S)-2-[(1S)-8-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=CC=C2CCO[C@@H](C=12)[C@H]1NCCC1 BEJLHUZAVNPBAT-WCQYABFASA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000012455 biphasic mixture Substances 0.000 description 9
- 238000004296 chiral HPLC Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- LTNZCRWPWRQSSL-CHWSQXEVSA-N (2R)-2-[(1R)-6-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC=1C=C2CCO[C@H](C2=CC=1)[C@@H]1NCCC1 LTNZCRWPWRQSSL-CHWSQXEVSA-N 0.000 description 8
- YDHXRLZTOOBMGJ-QWHCGFSZSA-N (2S)-2-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=C2CCO[C@H](C2=CC=1)[C@H]1NCCC1 YDHXRLZTOOBMGJ-QWHCGFSZSA-N 0.000 description 8
- YDHXRLZTOOBMGJ-STQMWFEESA-N (2S)-2-[(1S)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=C2CCO[C@@H](C2=CC=1)[C@H]1NCCC1 YDHXRLZTOOBMGJ-STQMWFEESA-N 0.000 description 8
- UWVWCCCPVOYMBW-GXTWGEPZSA-N (2S)-2-[(1S)-8-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC=1C=CC=C2CCO[C@@H](C=12)[C@H]1NCCC1 UWVWCCCPVOYMBW-GXTWGEPZSA-N 0.000 description 8
- GRTDLROMMMKRNI-UHFFFAOYSA-N 3-(2-bromo-4-fluorophenyl)propan-1-ol Chemical compound OCCCC1=CC=C(F)C=C1Br GRTDLROMMMKRNI-UHFFFAOYSA-N 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 8
- 208000028698 Cognitive impairment Diseases 0.000 description 8
- 208000014094 Dystonic disease Diseases 0.000 description 8
- 239000002249 anxiolytic agent Substances 0.000 description 8
- 208000010118 dystonia Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 238000010829 isocratic elution Methods 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- DQZIITQAMQMBEX-KBPBESRZSA-N (1S)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-6-carbonitrile Chemical compound N1[C@@H](CCC1)[C@H]1OCCC2=CC(=CC=C12)C#N DQZIITQAMQMBEX-KBPBESRZSA-N 0.000 description 7
- DCUNLAJPNLZLKF-OLZOCXBDSA-N (2R)-2-[(1S)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=C2CCO[C@@H](C2=CC=C1)[C@@H]1NCCC1 DCUNLAJPNLZLKF-OLZOCXBDSA-N 0.000 description 7
- LTNZCRWPWRQSSL-OLZOCXBDSA-N (2R)-2-[(1S)-6-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC=1C=C2CCO[C@@H](C2=CC=1)[C@@H]1NCCC1 LTNZCRWPWRQSSL-OLZOCXBDSA-N 0.000 description 7
- KRDOENPYPAXTFP-QWHCGFSZSA-N (2S)-2-[(1R)-6-bromo-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound BrC=1C=C2CCO[C@H](C2=CC=1)[C@H]1NCCC1 KRDOENPYPAXTFP-QWHCGFSZSA-N 0.000 description 7
- HGHGWIARSWGXPF-FRRDWIJNSA-N (2S)-2-[(1R,4S)-4,6-difluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound F[C@@H]1CO[C@H](C2=CC=C(C=C12)F)[C@H]1NCCC1 HGHGWIARSWGXPF-FRRDWIJNSA-N 0.000 description 7
- JFEOGPCGHOYTAE-KBPBESRZSA-N (2S)-2-[(1S)-3,3-dimethyl-1,4-dihydroisochromen-1-yl]pyrrolidine Chemical compound CC1(O[C@@H](C2=CC=CC=C2C1)[C@H]1NCCC1)C JFEOGPCGHOYTAE-KBPBESRZSA-N 0.000 description 7
- CGZRYUOFPWDYAN-RYUDHWBXSA-N (2S)-2-[(1S)-4,4-difluoro-1,3-dihydroisochromen-1-yl]pyrrolidine Chemical compound FC1(CO[C@@H](C2=CC=CC=C12)[C@H]1NCCC1)F CGZRYUOFPWDYAN-RYUDHWBXSA-N 0.000 description 7
- GRPJHCBAPZUHJT-RYUDHWBXSA-N (2S)-2-[(1S)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=C2CCO[C@@H](C2=CC=C1)[C@H]1NCC1 GRPJHCBAPZUHJT-RYUDHWBXSA-N 0.000 description 7
- DCUNLAJPNLZLKF-STQMWFEESA-N (2S)-2-[(1S)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=C2CCO[C@@H](C2=CC=C1)[C@H]1NCCC1 DCUNLAJPNLZLKF-STQMWFEESA-N 0.000 description 7
- DUVYLTNYKCCSSY-RYUDHWBXSA-N (2S)-2-[(1S)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=CC=C2CCO[C@@H](C2=C1)[C@H]1NCC1 DUVYLTNYKCCSSY-RYUDHWBXSA-N 0.000 description 7
- YFWZFYFLLIITTR-KBPBESRZSA-N (2S)-2-[(1S)-8-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(CCCO[C@@H]2[C@@H]2CCCN2)C=C1 YFWZFYFLLIITTR-KBPBESRZSA-N 0.000 description 7
- JREJOLJFGBYAPF-STQMWFEESA-N (3S)-3-[(1S)-3,4-dihydro-1H-isochromen-1-yl]morpholine Chemical compound C1COC[C@H](N1)[C@H]1OCCc2ccccc12 JREJOLJFGBYAPF-STQMWFEESA-N 0.000 description 7
- 206010034010 Parkinsonism Diseases 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- UEGGEIJWHPDPLL-ZETCQYMHSA-N tert-butyl (2s)-2-formylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H]1C=O UEGGEIJWHPDPLL-ZETCQYMHSA-N 0.000 description 7
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- DQZIITQAMQMBEX-KGLIPLIRSA-N (1S)-1-[(2R)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-6-carbonitrile Chemical compound N1[C@H](CCC1)[C@H]1OCCC2=CC(=CC=C12)C#N DQZIITQAMQMBEX-KGLIPLIRSA-N 0.000 description 6
- DLSFBQCEKLDFJT-KGLIPLIRSA-N (1S)-1-[(2R)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-7-carbonitrile Chemical compound N1[C@H](CCC1)[C@H]1OCCC2=CC=C(C=C12)C#N DLSFBQCEKLDFJT-KGLIPLIRSA-N 0.000 description 6
- DLSFBQCEKLDFJT-KBPBESRZSA-N (1S)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-7-carbonitrile Chemical compound N1[C@@H](CCC1)[C@H]1OCCC2=CC=C(C=C12)C#N DLSFBQCEKLDFJT-KBPBESRZSA-N 0.000 description 6
- AXQZRHBWWPEARS-RISCZKNCSA-N (2R)-2-[(1R)-8-methoxy-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound COC=1C=CC=C2CCO[C@H](C=12)[C@@H]1NCCC1 AXQZRHBWWPEARS-RISCZKNCSA-N 0.000 description 6
- BVMZKRBKTFTOHZ-HIFRSBDPSA-N (2R)-2-[(1R)-9-methyl-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound CC1=CC=CC2=C1[C@@H](OCCC2)[C@H]1CCCN1 BVMZKRBKTFTOHZ-HIFRSBDPSA-N 0.000 description 6
- APXJHCOUVNNZGL-KGLIPLIRSA-N (2R)-2-[(1S)-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound C1CN[C@H](C1)[C@H]1OCCCC2=C1C=CC=C2 APXJHCOUVNNZGL-KGLIPLIRSA-N 0.000 description 6
- RFUNBKOLXYJLTO-NEPJUHHUSA-N (2R)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound C1C[C@@H](N1)[C@H]1OCCc2ccccc12 RFUNBKOLXYJLTO-NEPJUHHUSA-N 0.000 description 6
- OOYKVQNGTZPJHK-OLZOCXBDSA-N (2R)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound C1CN[C@H](C1)[C@H]1OCCc2ccccc12 OOYKVQNGTZPJHK-OLZOCXBDSA-N 0.000 description 6
- WMNUEIVIDQRDCH-MNOVXSKESA-N (2R)-2-[(1S)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]azetidine Chemical compound FC1=CC=C2[C@H](OCC2=C1)[C@H]1CCN1 WMNUEIVIDQRDCH-MNOVXSKESA-N 0.000 description 6
- BRHMPAKAVCYAIB-NEPJUHHUSA-N (2R)-2-[(1S)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]pyrrolidine Chemical compound FC1=CC=C2[C@H](OCC2=C1)[C@H]1CCCN1 BRHMPAKAVCYAIB-NEPJUHHUSA-N 0.000 description 6
- GRPJHCBAPZUHJT-NEPJUHHUSA-N (2R)-2-[(1S)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=C2CCO[C@@H](C2=CC=C1)[C@@H]1NCC1 GRPJHCBAPZUHJT-NEPJUHHUSA-N 0.000 description 6
- XACMLRFYCQGELM-NEPJUHHUSA-N (2R)-2-[(1S)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC=1C=C2CCO[C@@H](C2=CC=1)[C@@H]1NCC1 XACMLRFYCQGELM-NEPJUHHUSA-N 0.000 description 6
- KXZUGKWNOQIFPG-OLZOCXBDSA-N (2R)-2-[(1S)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC1=CC=C2CCO[C@@H](C2=C1)[C@@H]1NCCC1 KXZUGKWNOQIFPG-OLZOCXBDSA-N 0.000 description 6
- NJHKNOLBQZGFCJ-KGLIPLIRSA-N (2R)-2-[(1S)-7-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(C=C1)[C@H](OCCC2)[C@H]1CCCN1 NJHKNOLBQZGFCJ-KGLIPLIRSA-N 0.000 description 6
- DUVYLTNYKCCSSY-NEPJUHHUSA-N (2R)-2-[(1S)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=CC=C2CCO[C@@H](C2=C1)[C@@H]1NCC1 DUVYLTNYKCCSSY-NEPJUHHUSA-N 0.000 description 6
- LICHVRMRYDTHLQ-OLZOCXBDSA-N (2R)-2-[(1S)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=CC=C2CCO[C@@H](C2=C1)[C@@H]1NCCC1 LICHVRMRYDTHLQ-OLZOCXBDSA-N 0.000 description 6
- LOQWJNZKJIBNOV-KGLIPLIRSA-N (2R)-2-[(1S)-7-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC1=CC=C2CCO[C@@H](C2=C1)[C@@H]1NCCC1 LOQWJNZKJIBNOV-KGLIPLIRSA-N 0.000 description 6
- YFWZFYFLLIITTR-KGLIPLIRSA-N (2R)-2-[(1S)-8-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(CCCO[C@@H]2[C@H]2CCCN2)C=C1 YFWZFYFLLIITTR-KGLIPLIRSA-N 0.000 description 6
- BEJLHUZAVNPBAT-DGCLKSJQSA-N (2R)-2-[(1S)-8-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=CC=C2CCO[C@@H](C=12)[C@@H]1NCCC1 BEJLHUZAVNPBAT-DGCLKSJQSA-N 0.000 description 6
- JFEOGPCGHOYTAE-UONOGXRCSA-N (2S)-2-[(1R)-3,3-dimethyl-1,4-dihydroisochromen-1-yl]pyrrolidine Chemical compound CC1(O[C@H](C2=CC=CC=C2C1)[C@H]1NCCC1)C JFEOGPCGHOYTAE-UONOGXRCSA-N 0.000 description 6
- LCUGETLBAITCCZ-GLXQMMQGSA-N (2S)-2-[(1R)-4,6-difluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1CO[C@H](C2=CC=C(C=C12)F)[C@H]1NCC1 LCUGETLBAITCCZ-GLXQMMQGSA-N 0.000 description 6
- BRHMPAKAVCYAIB-NWDGAFQWSA-N (2S)-2-[(1R)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]pyrrolidine Chemical compound FC1=CC=C2[C@@H](OCC2=C1)[C@@H]1CCCN1 BRHMPAKAVCYAIB-NWDGAFQWSA-N 0.000 description 6
- BEJLHUZAVNPBAT-AAEUAGOBSA-N (2S)-2-[(1R)-8-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=CC=C2CCO[C@H](C=12)[C@H]1NCCC1 BEJLHUZAVNPBAT-AAEUAGOBSA-N 0.000 description 6
- AXQZRHBWWPEARS-FZMZJTMJSA-N (2S)-2-[(1R)-8-methoxy-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound COC=1C=CC=C2CCO[C@H](C=12)[C@H]1NCCC1 AXQZRHBWWPEARS-FZMZJTMJSA-N 0.000 description 6
- APXJHCOUVNNZGL-KBPBESRZSA-N (2S)-2-[(1S)-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound C1CN[C@@H](C1)[C@H]1OCCCC2=C1C=CC=C2 APXJHCOUVNNZGL-KBPBESRZSA-N 0.000 description 6
- JSQHGDKFPSXZNJ-KBPBESRZSA-N (2S)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-4,4-dimethylpyrrolidine Chemical compound CC1(C)CN[C@@H](C1)[C@H]1OCCc2ccccc12 JSQHGDKFPSXZNJ-KBPBESRZSA-N 0.000 description 6
- RFUNBKOLXYJLTO-RYUDHWBXSA-N (2S)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound C1C[C@H](N1)[C@H]1OCCc2ccccc12 RFUNBKOLXYJLTO-RYUDHWBXSA-N 0.000 description 6
- DUZLZLCCNKGFKT-KBPBESRZSA-N (2S)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]piperidine Chemical compound C1CC[C@H](NC1)[C@H]1OCCc2ccccc12 DUZLZLCCNKGFKT-KBPBESRZSA-N 0.000 description 6
- OOYKVQNGTZPJHK-STQMWFEESA-N (2S)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound C1CN[C@@H](C1)[C@H]1OCCc2ccccc12 OOYKVQNGTZPJHK-STQMWFEESA-N 0.000 description 6
- LTNZCRWPWRQSSL-STQMWFEESA-N (2S)-2-[(1S)-6-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC=1C=C2CCO[C@@H](C2=CC=1)[C@H]1NCCC1 LTNZCRWPWRQSSL-STQMWFEESA-N 0.000 description 6
- XACMLRFYCQGELM-RYUDHWBXSA-N (2S)-2-[(1S)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC=1C=C2CCO[C@@H](C2=CC=1)[C@H]1NCC1 XACMLRFYCQGELM-RYUDHWBXSA-N 0.000 description 6
- SUZPKNYUOOCMQX-KBPBESRZSA-N (2S)-2-[(1S)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]piperidine Chemical compound FC=1C=C2CCO[C@@H](C2=CC=1)[C@H]1NCCCC1 SUZPKNYUOOCMQX-KBPBESRZSA-N 0.000 description 6
- KXZUGKWNOQIFPG-STQMWFEESA-N (2S)-2-[(1S)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC1=CC=C2CCO[C@@H](C2=C1)[C@H]1NCCC1 KXZUGKWNOQIFPG-STQMWFEESA-N 0.000 description 6
- NJHKNOLBQZGFCJ-KBPBESRZSA-N (2S)-2-[(1S)-7-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(C=C1)[C@H](OCCC2)[C@@H]1CCCN1 NJHKNOLBQZGFCJ-KBPBESRZSA-N 0.000 description 6
- LICHVRMRYDTHLQ-STQMWFEESA-N (2S)-2-[(1S)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=CC=C2CCO[C@@H](C2=C1)[C@H]1NCCC1 LICHVRMRYDTHLQ-STQMWFEESA-N 0.000 description 6
- LOQWJNZKJIBNOV-KBPBESRZSA-N (2S)-2-[(1S)-7-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC1=CC=C2CCO[C@@H](C2=C1)[C@H]1NCCC1 LOQWJNZKJIBNOV-KBPBESRZSA-N 0.000 description 6
- RVZPQLGMKJJIBP-CMPLNLGQSA-N (2S)-2-[(1S)-8-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC=1C=CC=C2CCO[C@@H](C=12)[C@H]1NCC1 RVZPQLGMKJJIBP-CMPLNLGQSA-N 0.000 description 6
- AXQZRHBWWPEARS-SMDDNHRTSA-N (2S)-2-[(1S)-8-methoxy-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound COC=1C=CC=C2CCO[C@@H](C=12)[C@H]1NCCC1 AXQZRHBWWPEARS-SMDDNHRTSA-N 0.000 description 6
- BVMZKRBKTFTOHZ-DZGCQCFKSA-N (2S)-2-[(1S)-9-methyl-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound CC1=CC=CC2=C1[C@H](OCCC2)[C@@H]1CCCN1 BVMZKRBKTFTOHZ-DZGCQCFKSA-N 0.000 description 6
- HPAZWGJHLBTKGW-STQMWFEESA-N (3S)-3-[(1S)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]morpholine Chemical compound FC=1C=C2CCO[C@@H](C2=CC=1)[C@H]1NCCOC1 HPAZWGJHLBTKGW-STQMWFEESA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- FYKRRAQLEDQAJV-ROUUACIJSA-N 2-[(1S)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromen-6-yl]pyridine Chemical compound N1[C@@H](CCC1)[C@H]1OCCC2=CC(=CC=C12)C1=NC=CC=C1 FYKRRAQLEDQAJV-ROUUACIJSA-N 0.000 description 6
- RLLDQQWRYQOVBQ-GFCCVEGCSA-N 3-[(1R)-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound C1NCC1[C@H]1OCCc2ccccc12 RLLDQQWRYQOVBQ-GFCCVEGCSA-N 0.000 description 6
- RHJAJARQBYFNBC-CYBMUJFWSA-N 3-[(1R)-7-methyl-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound CC1=CC=C2CCO[C@@H](C2=C1)C1CNC1 RHJAJARQBYFNBC-CYBMUJFWSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000164 antipsychotic agent Substances 0.000 description 6
- 229940005529 antipsychotics Drugs 0.000 description 6
- 230000000949 anxiolytic effect Effects 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000002287 radioligand Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- DQZIITQAMQMBEX-ZIAGYGMSSA-N (1R)-1-[(2R)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-6-carbonitrile Chemical compound N1[C@H](CCC1)[C@@H]1OCCC2=CC(=CC=C12)C#N DQZIITQAMQMBEX-ZIAGYGMSSA-N 0.000 description 5
- DLSFBQCEKLDFJT-ZIAGYGMSSA-N (1R)-1-[(2R)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-7-carbonitrile Chemical compound N1[C@H](CCC1)[C@@H]1OCCC2=CC=C(C=C12)C#N DLSFBQCEKLDFJT-ZIAGYGMSSA-N 0.000 description 5
- DLSFBQCEKLDFJT-UONOGXRCSA-N (1R)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-7-carbonitrile Chemical compound N1[C@@H](CCC1)[C@@H]1OCCC2=CC=C(C=C12)C#N DLSFBQCEKLDFJT-UONOGXRCSA-N 0.000 description 5
- APXJHCOUVNNZGL-ZIAGYGMSSA-N (2R)-2-[(1R)-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound C1CN[C@H](C1)[C@@H]1OCCCC2=C1C=CC=C2 APXJHCOUVNNZGL-ZIAGYGMSSA-N 0.000 description 5
- JFEOGPCGHOYTAE-ZIAGYGMSSA-N (2R)-2-[(1R)-3,3-dimethyl-1,4-dihydroisochromen-1-yl]pyrrolidine Chemical compound CC1(O[C@H](C2=CC=CC=C2C1)[C@@H]1NCCC1)C JFEOGPCGHOYTAE-ZIAGYGMSSA-N 0.000 description 5
- RFUNBKOLXYJLTO-VXGBXAGGSA-N (2R)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@@H]1NCC1 RFUNBKOLXYJLTO-VXGBXAGGSA-N 0.000 description 5
- OOYKVQNGTZPJHK-CHWSQXEVSA-N (2R)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@@H]1NCCC1 OOYKVQNGTZPJHK-CHWSQXEVSA-N 0.000 description 5
- WMNUEIVIDQRDCH-GHMZBOCLSA-N (2R)-2-[(1R)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]azetidine Chemical compound FC1=CC=C2[C@@H](OCC2=C1)[C@H]1CCN1 WMNUEIVIDQRDCH-GHMZBOCLSA-N 0.000 description 5
- BRHMPAKAVCYAIB-VXGBXAGGSA-N (2R)-2-[(1R)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]pyrrolidine Chemical compound FC1=CC=C2[C@@H](OCC2=C1)[C@H]1CCCN1 BRHMPAKAVCYAIB-VXGBXAGGSA-N 0.000 description 5
- DYZKMPFYUCXMBX-CHWSQXEVSA-N (2R)-2-[(1R)-5-fluoro-1-methyl-3H-2-benzofuran-1-yl]pyrrolidine Chemical compound C[C@]1(OCC2=CC(F)=CC=C12)[C@H]1CCCN1 DYZKMPFYUCXMBX-CHWSQXEVSA-N 0.000 description 5
- GRPJHCBAPZUHJT-VXGBXAGGSA-N (2R)-2-[(1R)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=C2CCO[C@H](C2=CC=C1)[C@@H]1NCC1 GRPJHCBAPZUHJT-VXGBXAGGSA-N 0.000 description 5
- XACMLRFYCQGELM-VXGBXAGGSA-N (2R)-2-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC=1C=C2CCO[C@H](C2=CC=1)[C@@H]1NCC1 XACMLRFYCQGELM-VXGBXAGGSA-N 0.000 description 5
- KXZUGKWNOQIFPG-CHWSQXEVSA-N (2R)-2-[(1R)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC1=CC=C2CCO[C@H](C2=C1)[C@@H]1NCCC1 KXZUGKWNOQIFPG-CHWSQXEVSA-N 0.000 description 5
- NJHKNOLBQZGFCJ-ZIAGYGMSSA-N (2R)-2-[(1R)-7-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(C=C1)[C@@H](OCCC2)[C@H]1CCCN1 NJHKNOLBQZGFCJ-ZIAGYGMSSA-N 0.000 description 5
- DUVYLTNYKCCSSY-VXGBXAGGSA-N (2R)-2-[(1R)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=CC=C2CCO[C@H](C2=C1)[C@@H]1NCC1 DUVYLTNYKCCSSY-VXGBXAGGSA-N 0.000 description 5
- LICHVRMRYDTHLQ-CHWSQXEVSA-N (2R)-2-[(1R)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=CC=C2CCO[C@H](C2=C1)[C@@H]1NCCC1 LICHVRMRYDTHLQ-CHWSQXEVSA-N 0.000 description 5
- LOQWJNZKJIBNOV-ZIAGYGMSSA-N (2R)-2-[(1R)-7-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC1=CC=C2CCO[C@H](C2=C1)[C@@H]1NCCC1 LOQWJNZKJIBNOV-ZIAGYGMSSA-N 0.000 description 5
- YFWZFYFLLIITTR-ZIAGYGMSSA-N (2R)-2-[(1R)-8-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(CCCO[C@H]2[C@H]2CCCN2)C=C1 YFWZFYFLLIITTR-ZIAGYGMSSA-N 0.000 description 5
- BEJLHUZAVNPBAT-YPMHNXCESA-N (2R)-2-[(1R)-8-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=CC=C2CCO[C@H](C=12)[C@@H]1NCCC1 BEJLHUZAVNPBAT-YPMHNXCESA-N 0.000 description 5
- UWVWCCCPVOYMBW-OCCSQVGLSA-N (2R)-2-[(1R)-8-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC=1C=CC=C2CCO[C@H](C=12)[C@@H]1NCCC1 UWVWCCCPVOYMBW-OCCSQVGLSA-N 0.000 description 5
- JFEOGPCGHOYTAE-KGLIPLIRSA-N (2R)-2-[(1S)-3,3-dimethyl-1,4-dihydroisochromen-1-yl]pyrrolidine Chemical compound CC1(O[C@@H](C2=CC=CC=C2C1)[C@@H]1NCCC1)C JFEOGPCGHOYTAE-KGLIPLIRSA-N 0.000 description 5
- UWVWCCCPVOYMBW-TZMCWYRMSA-N (2R)-2-[(1S)-8-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC=1C=CC=C2CCO[C@@H](C=12)[C@@H]1NCCC1 UWVWCCCPVOYMBW-TZMCWYRMSA-N 0.000 description 5
- BVMZKRBKTFTOHZ-UKRRQHHQSA-N (2R)-2-[(1S)-9-methyl-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound CC1=CC=CC2=C1[C@H](OCCC2)[C@H]1CCCN1 BVMZKRBKTFTOHZ-UKRRQHHQSA-N 0.000 description 5
- APXJHCOUVNNZGL-UONOGXRCSA-N (2S)-2-[(1R)-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound C1CN[C@@H](C1)[C@@H]1OCCCC2=C1C=CC=C2 APXJHCOUVNNZGL-UONOGXRCSA-N 0.000 description 5
- ZNNHNGCRKAQCMI-NWDGAFQWSA-N (2S)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-4,4-difluoropyrrolidine Chemical compound FC1(C[C@H](NC1)[C@@H]1OCCC2=CC=CC=C12)F ZNNHNGCRKAQCMI-NWDGAFQWSA-N 0.000 description 5
- JSQHGDKFPSXZNJ-UONOGXRCSA-N (2S)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-4,4-dimethylpyrrolidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@H]1NCC(C1)(C)C JSQHGDKFPSXZNJ-UONOGXRCSA-N 0.000 description 5
- RFUNBKOLXYJLTO-NWDGAFQWSA-N (2S)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@H]1NCC1 RFUNBKOLXYJLTO-NWDGAFQWSA-N 0.000 description 5
- DUZLZLCCNKGFKT-UONOGXRCSA-N (2S)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]piperidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@H]1NCCCC1 DUZLZLCCNKGFKT-UONOGXRCSA-N 0.000 description 5
- OOYKVQNGTZPJHK-QWHCGFSZSA-N (2S)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@H]1NCCC1 OOYKVQNGTZPJHK-QWHCGFSZSA-N 0.000 description 5
- LTNZCRWPWRQSSL-QWHCGFSZSA-N (2S)-2-[(1R)-6-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC=1C=C2CCO[C@H](C2=CC=1)[C@H]1NCCC1 LTNZCRWPWRQSSL-QWHCGFSZSA-N 0.000 description 5
- XACMLRFYCQGELM-NWDGAFQWSA-N (2S)-2-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC=1C=C2CCO[C@H](C2=CC=1)[C@H]1NCC1 XACMLRFYCQGELM-NWDGAFQWSA-N 0.000 description 5
- SUZPKNYUOOCMQX-UONOGXRCSA-N (2S)-2-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]piperidine Chemical compound FC=1C=C2CCO[C@H](C2=CC=1)[C@H]1NCCCC1 SUZPKNYUOOCMQX-UONOGXRCSA-N 0.000 description 5
- KXZUGKWNOQIFPG-QWHCGFSZSA-N (2S)-2-[(1R)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound ClC1=CC=C2CCO[C@H](C2=C1)[C@H]1NCCC1 KXZUGKWNOQIFPG-QWHCGFSZSA-N 0.000 description 5
- NJHKNOLBQZGFCJ-UONOGXRCSA-N (2S)-2-[(1R)-7-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(C=C1)[C@@H](OCCC2)[C@@H]1CCCN1 NJHKNOLBQZGFCJ-UONOGXRCSA-N 0.000 description 5
- LICHVRMRYDTHLQ-QWHCGFSZSA-N (2S)-2-[(1R)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=CC=C2CCO[C@H](C2=C1)[C@H]1NCCC1 LICHVRMRYDTHLQ-QWHCGFSZSA-N 0.000 description 5
- LOQWJNZKJIBNOV-UONOGXRCSA-N (2S)-2-[(1R)-7-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC1=CC=C2CCO[C@H](C2=C1)[C@H]1NCCC1 LOQWJNZKJIBNOV-UONOGXRCSA-N 0.000 description 5
- RVZPQLGMKJJIBP-JQWIXIFHSA-N (2S)-2-[(1R)-8-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC=1C=CC=C2CCO[C@H](C=12)[C@H]1NCC1 RVZPQLGMKJJIBP-JQWIXIFHSA-N 0.000 description 5
- BVMZKRBKTFTOHZ-ZFWWWQNUSA-N (2S)-2-[(1R)-9-methyl-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound CC1=CC=CC2=C1[C@@H](OCCC2)[C@@H]1CCCN1 BVMZKRBKTFTOHZ-ZFWWWQNUSA-N 0.000 description 5
- HGHGWIARSWGXPF-RWMBFGLXSA-N (2S)-2-[(1R,4R)-4,6-difluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound F[C@H]1CO[C@H](C2=CC=C(C=C12)F)[C@H]1NCCC1 HGHGWIARSWGXPF-RWMBFGLXSA-N 0.000 description 5
- ZNNHNGCRKAQCMI-RYUDHWBXSA-N (2S)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-4,4-difluoropyrrolidine Chemical compound FC1(C[C@H](NC1)[C@H]1OCCC2=CC=CC=C12)F ZNNHNGCRKAQCMI-RYUDHWBXSA-N 0.000 description 5
- LCUGETLBAITCCZ-RAMGSTBQSA-N (2S)-2-[(1S)-4,6-difluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1CO[C@H]([C@@H]2CCN2)C2=CC=C(F)C=C12 LCUGETLBAITCCZ-RAMGSTBQSA-N 0.000 description 5
- JYRNDNQGVUGSAG-CABZTGNLSA-N (2S)-2-[(8R)-6,8-dihydrofuro[3,4-g][1,3]benzodioxol-8-yl]pyrrolidine Chemical compound C1CN[C@@H](C1)[C@@H]1OCC2=CC=C3OCOC3=C12 JYRNDNQGVUGSAG-CABZTGNLSA-N 0.000 description 5
- JREJOLJFGBYAPF-QWHCGFSZSA-N (3S)-3-[(1R)-3,4-dihydro-1H-isochromen-1-yl]morpholine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@H]1NCCOC1 JREJOLJFGBYAPF-QWHCGFSZSA-N 0.000 description 5
- HPAZWGJHLBTKGW-QWHCGFSZSA-N (3S)-3-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]morpholine Chemical compound FC=1C=C2CCO[C@H](C2=CC=1)[C@H]1NCCOC1 HPAZWGJHLBTKGW-QWHCGFSZSA-N 0.000 description 5
- PTTFLKHCSZSFOL-UHFFFAOYSA-N 2-(3-bromophenyl)ethanol Chemical compound OCCC1=CC=CC(Br)=C1 PTTFLKHCSZSFOL-UHFFFAOYSA-N 0.000 description 5
- MZNBGEKFZCWVES-UHFFFAOYSA-N 2-(3-fluorophenyl)ethanol Chemical compound OCCC1=CC=CC(F)=C1 MZNBGEKFZCWVES-UHFFFAOYSA-N 0.000 description 5
- ZQIRSPVHSNADGR-UHFFFAOYSA-N 2-[(2-bromo-5-fluorophenyl)methoxy]oxane Chemical compound FC1=CC=C(Br)C(COC2OCCCC2)=C1 ZQIRSPVHSNADGR-UHFFFAOYSA-N 0.000 description 5
- RHJAJARQBYFNBC-ZDUSSCGKSA-N 3-[(1S)-7-methyl-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound CC1=CC=C2CCO[C@H](C2=C1)C1CNC1 RHJAJARQBYFNBC-ZDUSSCGKSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 208000000044 Amnesia Diseases 0.000 description 5
- 208000031091 Amnestic disease Diseases 0.000 description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 5
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 5
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 208000019022 Mood disease Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 206010007776 catatonia Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 208000024732 dysthymic disease Diseases 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 229960001078 lithium Drugs 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- 239000004050 mood stabilizer Substances 0.000 description 5
- 229940127237 mood stabilizer Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- DQZIITQAMQMBEX-UONOGXRCSA-N (1R)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-6-carbonitrile Chemical compound N1[C@@H](CCC1)[C@@H]1OCCC2=CC(=CC=C12)C#N DQZIITQAMQMBEX-UONOGXRCSA-N 0.000 description 4
- HIEVZUIEZJLCDT-TZMCWYRMSA-N (1S)-1-[(2R)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-8-carbonitrile Chemical compound N1[C@H](CCC1)[C@H]1OCCC2=CC=CC(=C12)C#N HIEVZUIEZJLCDT-TZMCWYRMSA-N 0.000 description 4
- DCUNLAJPNLZLKF-CHWSQXEVSA-N (2R)-2-[(1R)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=C2CCO[C@H](C2=CC=C1)[C@@H]1NCCC1 DCUNLAJPNLZLKF-CHWSQXEVSA-N 0.000 description 4
- DYZKMPFYUCXMBX-OLZOCXBDSA-N (2R)-2-[(1S)-5-fluoro-1-methyl-3H-2-benzofuran-1-yl]pyrrolidine Chemical compound C[C@@]1(OCC2=CC(F)=CC=C12)[C@H]1CCCN1 DYZKMPFYUCXMBX-OLZOCXBDSA-N 0.000 description 4
- YDHXRLZTOOBMGJ-OLZOCXBDSA-N (2R)-2-[(1S)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=C2CCO[C@@H](C2=CC=1)[C@@H]1NCCC1 YDHXRLZTOOBMGJ-OLZOCXBDSA-N 0.000 description 4
- AXQZRHBWWPEARS-BXUZGUMPSA-N (2R)-2-[(1S)-8-methoxy-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound COC=1C=CC=C2CCO[C@@H](C=12)[C@@H]1NCCC1 AXQZRHBWWPEARS-BXUZGUMPSA-N 0.000 description 4
- DYIROVHTMMFKEB-LSDHHAIUSA-N (2S)-1-ethyl-2-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound C(C)N1[C@@H](CCC1)[C@@H]1OCCC2=CC(=CC=C12)F DYIROVHTMMFKEB-LSDHHAIUSA-N 0.000 description 4
- CGZRYUOFPWDYAN-NWDGAFQWSA-N (2S)-2-[(1R)-4,4-difluoro-1,3-dihydroisochromen-1-yl]pyrrolidine Chemical compound FC1(CO[C@H](C2=CC=CC=C12)[C@H]1NCCC1)F CGZRYUOFPWDYAN-NWDGAFQWSA-N 0.000 description 4
- DYZKMPFYUCXMBX-QWHCGFSZSA-N (2S)-2-[(1R)-5-fluoro-1-methyl-3H-2-benzofuran-1-yl]pyrrolidine Chemical compound C[C@]1(OCC2=CC(F)=CC=C12)[C@@H]1CCCN1 DYZKMPFYUCXMBX-QWHCGFSZSA-N 0.000 description 4
- GRPJHCBAPZUHJT-NWDGAFQWSA-N (2S)-2-[(1R)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=C2CCO[C@H](C2=CC=C1)[C@H]1NCC1 GRPJHCBAPZUHJT-NWDGAFQWSA-N 0.000 description 4
- DCUNLAJPNLZLKF-QWHCGFSZSA-N (2S)-2-[(1R)-5-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC1=C2CCO[C@H](C2=CC=C1)[C@H]1NCCC1 DCUNLAJPNLZLKF-QWHCGFSZSA-N 0.000 description 4
- DUVYLTNYKCCSSY-NWDGAFQWSA-N (2S)-2-[(1R)-7-fluoro-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound FC1=CC=C2CCO[C@H](C2=C1)[C@H]1NCC1 DUVYLTNYKCCSSY-NWDGAFQWSA-N 0.000 description 4
- UWVWCCCPVOYMBW-JSGCOSHPSA-N (2S)-2-[(1R)-8-methyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound CC=1C=CC=C2CCO[C@H](C=12)[C@H]1NCCC1 UWVWCCCPVOYMBW-JSGCOSHPSA-N 0.000 description 4
- DYZKMPFYUCXMBX-STQMWFEESA-N (2S)-2-[(1S)-5-fluoro-1-methyl-3H-2-benzofuran-1-yl]pyrrolidine Chemical compound C[C@@]1(OCC2=CC(F)=CC=C12)[C@@H]1CCCN1 DYZKMPFYUCXMBX-STQMWFEESA-N 0.000 description 4
- RLLDQQWRYQOVBQ-LBPRGKRZSA-N 3-[(1S)-3,4-dihydro-1H-isochromen-1-yl]azetidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)C1CNC1 RLLDQQWRYQOVBQ-LBPRGKRZSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000020706 Autistic disease Diseases 0.000 description 4
- 208000030336 Bipolar and Related disease Diseases 0.000 description 4
- 206010008748 Chorea Diseases 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000004547 Hallucinations Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 206010041250 Social phobia Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000016571 aggressive behavior Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000006986 amnesia Effects 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 208000012601 choreatic disease Diseases 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- 201000003631 narcolepsy Diseases 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- OTJGJTFFNJECOJ-NNJIEVJOSA-N tert-butyl (2R)-2-[1-[4-fluoro-2-(hydroxymethyl)phenyl]-1-hydroxyethyl]pyrrolidine-1-carboxylate Chemical compound FC1=CC(=C(C=C1)C(C)(O)[C@@H]1N(CCC1)C(=O)OC(C)(C)C)CO OTJGJTFFNJECOJ-NNJIEVJOSA-N 0.000 description 4
- UEGGEIJWHPDPLL-SSDOTTSWSA-N tert-butyl (2r)-2-formylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H]1C=O UEGGEIJWHPDPLL-SSDOTTSWSA-N 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- HIEVZUIEZJLCDT-GXTWGEPZSA-N (1S)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-8-carbonitrile Chemical compound N1[C@@H](CCC1)[C@H]1OCCC2=CC=CC(=C12)C#N HIEVZUIEZJLCDT-GXTWGEPZSA-N 0.000 description 3
- JSQHGDKFPSXZNJ-KGLIPLIRSA-N (2R)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-4,4-dimethylpyrrolidine Chemical compound CC1(C)CN[C@H](C1)[C@H]1OCCc2ccccc12 JSQHGDKFPSXZNJ-KGLIPLIRSA-N 0.000 description 3
- OOYKVQNGTZPJHK-UEWDXFNNSA-N (2S)-2-(3,4-dihydro-1H-isochromen-1-yl)pyrrolidine Chemical compound C1(OCCC2=CC=CC=C12)[C@H]1NCCC1 OOYKVQNGTZPJHK-UEWDXFNNSA-N 0.000 description 3
- WMNUEIVIDQRDCH-WDEREUQCSA-N (2S)-2-[(1R)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]azetidine Chemical compound FC1=CC=C2[C@@H](OCC2=C1)[C@@H]1CCN1 WMNUEIVIDQRDCH-WDEREUQCSA-N 0.000 description 3
- YFWZFYFLLIITTR-UONOGXRCSA-N (2S)-2-[(1R)-8-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC2=C(CCCO[C@H]2[C@@H]2CCCN2)C=C1 YFWZFYFLLIITTR-UONOGXRCSA-N 0.000 description 3
- CXBZHLIQIJBOIN-JSGCOSHPSA-N (2S)-2-[(1R)-9-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl]pyrrolidine Chemical compound FC1=CC=CC2=C1[C@@H](OCCC2)[C@@H]1CCCN1 CXBZHLIQIJBOIN-JSGCOSHPSA-N 0.000 description 3
- WMNUEIVIDQRDCH-QWRGUYRKSA-N (2S)-2-[(1S)-5-fluoro-1,3-dihydro-2-benzofuran-1-yl]azetidine Chemical compound FC1=CC=C2[C@H](OCC2=C1)[C@@H]1CCN1 WMNUEIVIDQRDCH-QWRGUYRKSA-N 0.000 description 3
- KRDOENPYPAXTFP-STQMWFEESA-N (2S)-2-[(1S)-6-bromo-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound BrC=1C=C2CCO[C@@H](C2=CC=1)[C@H]1NCCC1 KRDOENPYPAXTFP-STQMWFEESA-N 0.000 description 3
- UXQJCRYQCNOUMH-UHFFFAOYSA-N 1-(2-bromophenyl)-2-methylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1Br UXQJCRYQCNOUMH-UHFFFAOYSA-N 0.000 description 3
- HNIGZVZDWCTFPR-UHFFFAOYSA-N 2-(2-fluorophenyl)ethanol Chemical compound OCCC1=CC=CC=C1F HNIGZVZDWCTFPR-UHFFFAOYSA-N 0.000 description 3
- VVTSEHTUHJLISV-ZSOXZCCMSA-N 4-[hydroxy-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]methyl]-1,3-benzodioxole-5-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)C1=C(C=CC2=C1OCO2)C(O)=O VVTSEHTUHJLISV-ZSOXZCCMSA-N 0.000 description 3
- SBFNIFZMRLDUNB-HOCLYGCPSA-N 5-[(1S)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromen-6-yl]-1,2-oxazole Chemical compound N1[C@@H](CCC1)[C@H]1OCCC2=CC(=CC=C12)C1=CC=NO1 SBFNIFZMRLDUNB-HOCLYGCPSA-N 0.000 description 3
- WFEHCHZUPYHPOT-VSGBNLITSA-N 9H-fluoren-9-ylmethyl (2R)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-4,4-dimethylpyrrolidine-1-carboxylate Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@@H]1N(CC(C1)(C)C)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 WFEHCHZUPYHPOT-VSGBNLITSA-N 0.000 description 3
- QMMPTFILKKLIGO-IGKIAQTJSA-N 9H-fluoren-9-ylmethyl (2S)-2-[(1R)-8-hydroxy-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound OC=1C=CC=C2CCO[C@H](C=12)[C@H]1N(CCC1)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 QMMPTFILKKLIGO-IGKIAQTJSA-N 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- 206010003805 Autism Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 201000010374 Down Syndrome Diseases 0.000 description 3
- 208000011688 Generalised anxiety disease Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 3
- 208000002033 Myoclonus Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010034912 Phobia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000007131 anti Alzheimer effect Effects 0.000 description 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229960002802 bromocriptine Drugs 0.000 description 3
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000029364 generalized anxiety disease Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 206010020765 hypersomnia Diseases 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 239000003176 neuroleptic agent Substances 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960003089 pramipexole Drugs 0.000 description 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000004461 rapid eye movement Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 208000022610 schizoaffective disease Diseases 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 201000002859 sleep apnea Diseases 0.000 description 3
- 230000003997 social interaction Effects 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- GOFGCXUIGDLMLK-RZFJCUDFSA-N tert-butyl (2R)-2-[1-[4-fluoro-2-(oxan-2-yloxymethyl)phenyl]-1-hydroxyethyl]pyrrolidine-1-carboxylate Chemical compound FC1=CC(=C(C=C1)C(C)(O)[C@@H]1N(CCC1)C(=O)OC(C)(C)C)COC1OCCCC1 GOFGCXUIGDLMLK-RZFJCUDFSA-N 0.000 description 3
- AMNZCRWIUDPMOK-BHWOMJMDSA-N tert-butyl (2S)-2-(3,3-dimethyl-1,4-dihydroisochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound CC1(OC(C2=CC=CC=C2C1)[C@H]1N(CCC1)C(=O)OC(C)(C)C)C AMNZCRWIUDPMOK-BHWOMJMDSA-N 0.000 description 3
- DASXALMANIAPBB-PCKAHOCUSA-N tert-butyl (2S)-2-(4,6-difluoro-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound FC1COC(C2=CC=C(C=C12)F)[C@H]1N(CCC1)C(=O)OC(C)(C)C DASXALMANIAPBB-PCKAHOCUSA-N 0.000 description 3
- KQSKNFJXSXZGRK-LBAUFKAWSA-N tert-butyl (2S)-2-(5-bromo-8-fluoro-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](CCC1)C1OCCC2=C(C=CC(=C12)F)Br KQSKNFJXSXZGRK-LBAUFKAWSA-N 0.000 description 3
- GRMMTMMBTSTZOY-VYRBHSGPSA-N tert-butyl (2S)-2-(6-bromo-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound BrC=1C=C2CCOC(C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C GRMMTMMBTSTZOY-VYRBHSGPSA-N 0.000 description 3
- GRMMTMMBTSTZOY-HOTGVXAUSA-N tert-butyl (2S)-2-[(1S)-6-bromo-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound BrC=1C=C2CCO[C@@H](C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C GRMMTMMBTSTZOY-HOTGVXAUSA-N 0.000 description 3
- HLSMXLFZMJISCP-OAHLLOKOSA-N tert-butyl 3-[(1R)-3,4-dihydro-1H-isochromen-1-yl]azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C1)[C@H]1OCCc2ccccc12 HLSMXLFZMJISCP-OAHLLOKOSA-N 0.000 description 3
- HLSMXLFZMJISCP-HNNXBMFYSA-N tert-butyl 3-[(1S)-3,4-dihydro-1H-isochromen-1-yl]azetidine-1-carboxylate Chemical compound [C@H]1(OCCC2=CC=CC=C12)C1CN(C1)C(=O)OC(C)(C)C HLSMXLFZMJISCP-HNNXBMFYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 3
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 3
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 2
- HXGZPMHPSBJMKB-UHFFFAOYSA-N (2-bromo-5-fluorophenyl)methanol Chemical compound OCC1=CC(F)=CC=C1Br HXGZPMHPSBJMKB-UHFFFAOYSA-N 0.000 description 2
- VCFQSOOKBJTVKF-UHFFFAOYSA-N (2-bromo-5-fluorophenyl)methoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(F)=CC=C1Br VCFQSOOKBJTVKF-UHFFFAOYSA-N 0.000 description 2
- JSQHGDKFPSXZNJ-ZIAGYGMSSA-N (2R)-2-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-4,4-dimethylpyrrolidine Chemical compound [C@H]1(OCCC2=CC=CC=C12)[C@@H]1NCC(C1)(C)C JSQHGDKFPSXZNJ-ZIAGYGMSSA-N 0.000 description 2
- YDHXRLZTOOBMGJ-CHWSQXEVSA-N (2R)-2-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine Chemical compound FC=1C=C2CCO[C@H](C2=CC=1)[C@@H]1NCCC1 YDHXRLZTOOBMGJ-CHWSQXEVSA-N 0.000 description 2
- JFEOGPCGHOYTAE-LSLKUGRBSA-N (2S)-2-(3,3-dimethyl-1,4-dihydroisochromen-1-yl)pyrrolidine Chemical compound CC1(OC(C2=CC=CC=C2C1)[C@H]1NCCC1)C JFEOGPCGHOYTAE-LSLKUGRBSA-N 0.000 description 2
- YDHXRLZTOOBMGJ-UEWDXFNNSA-N (2S)-2-(6-fluoro-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine Chemical compound FC=1C=C2CCOC(C2=CC=1)[C@H]1NCCC1 YDHXRLZTOOBMGJ-UEWDXFNNSA-N 0.000 description 2
- YFWZFYFLLIITTR-LSLKUGRBSA-N (2S)-2-(8-fluoro-1,3,4,5-tetrahydro-2-benzoxepin-1-yl)pyrrolidine Chemical compound FC1=CC2=C(CCCOC2[C@@H]2CCCN2)C=C1 YFWZFYFLLIITTR-LSLKUGRBSA-N 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- AVHIUBUCWYRMQV-UHFFFAOYSA-N 2-(2-bromo-4-fluorophenyl)ethanol Chemical compound OCCC1=CC=C(F)C=C1Br AVHIUBUCWYRMQV-UHFFFAOYSA-N 0.000 description 2
- NCVWURWGRQEAAU-UHFFFAOYSA-N 2-(2-bromo-5-methoxyphenyl)ethanol Chemical compound COC1=CC=C(Br)C(CCO)=C1 NCVWURWGRQEAAU-UHFFFAOYSA-N 0.000 description 2
- HXHFPLLPFMVPFV-UHFFFAOYSA-N 2-(2-bromo-5-methylphenyl)ethanol Chemical compound CC1=CC=C(Br)C(CCO)=C1 HXHFPLLPFMVPFV-UHFFFAOYSA-N 0.000 description 2
- PHFIKLUHTYXQSP-UHFFFAOYSA-N 2-(2-bromophenyl)ethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC=C1Br PHFIKLUHTYXQSP-UHFFFAOYSA-N 0.000 description 2
- NDWAVJKRSASRPH-UHFFFAOYSA-N 2-(3-chlorophenyl)ethanol Chemical compound OCCC1=CC=CC(Cl)=C1 NDWAVJKRSASRPH-UHFFFAOYSA-N 0.000 description 2
- HZFRKZWBVUJYDA-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanol Chemical compound OCCC1=CC=C(Cl)C=C1 HZFRKZWBVUJYDA-UHFFFAOYSA-N 0.000 description 2
- DAVFJRVIVZOKKS-UHFFFAOYSA-N 2-(4-methylphenyl)ethanol Chemical compound CC1=CC=C(CCO)C=C1 DAVFJRVIVZOKKS-UHFFFAOYSA-N 0.000 description 2
- FYKRRAQLEDQAJV-ZWKOTPCHSA-N 2-[(1R)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromen-6-yl]pyridine Chemical compound N1[C@@H](CCC1)[C@@H]1OCCC2=CC(=CC=C12)C1=NC=CC=C1 FYKRRAQLEDQAJV-ZWKOTPCHSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- YTYNUXUANDQHLA-UHFFFAOYSA-N 3-(2-bromo-3-methylphenyl)propan-1-ol Chemical compound CC1=CC=CC(CCCO)=C1Br YTYNUXUANDQHLA-UHFFFAOYSA-N 0.000 description 2
- SZNSMAMFXJZGAW-UHFFFAOYSA-N 3-(2-bromo-4-fluorophenyl)propoxy-tert-butyl-dimethylsilane Chemical compound BrC1=C(C=CC(=C1)F)CCCO[Si](C)(C)C(C)(C)C SZNSMAMFXJZGAW-UHFFFAOYSA-N 0.000 description 2
- XTDALYXYEGSCCZ-UHFFFAOYSA-N 3-(2-bromo-5-fluorophenyl)propan-1-ol Chemical compound OCCCC1=CC(F)=CC=C1Br XTDALYXYEGSCCZ-UHFFFAOYSA-N 0.000 description 2
- VODAJGPTULSNSU-UHFFFAOYSA-N 3-(2-bromophenyl)propan-1-ol Chemical compound OCCCC1=CC=CC=C1Br VODAJGPTULSNSU-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- MWUVGXCUHWKQJE-UHFFFAOYSA-N 4-fluorophenethyl alcohol Chemical compound OCCC1=CC=C(F)C=C1 MWUVGXCUHWKQJE-UHFFFAOYSA-N 0.000 description 2
- SBFNIFZMRLDUNB-GOEBONIOSA-N 5-[(1R)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromen-6-yl]-1,2-oxazole Chemical compound N1[C@@H](CCC1)[C@@H]1OCCC2=CC(=CC=C12)C1=CC=NO1 SBFNIFZMRLDUNB-GOEBONIOSA-N 0.000 description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- DSQQHDPVGPZZKE-OAHLLOKOSA-N 9H-fluoren-9-ylmethyl (2R)-2-(hydroxymethyl)-4,4-dimethylpyrrolidine-1-carboxylate Chemical compound OC[C@@H]1N(CC(C1)(C)C)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 DSQQHDPVGPZZKE-OAHLLOKOSA-N 0.000 description 2
- WFEHCHZUPYHPOT-IZLXSDGUSA-N 9H-fluoren-9-ylmethyl (2R)-2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-4,4-dimethylpyrrolidine-1-carboxylate Chemical compound CC1(C)C[C@H]([C@H]2OCCc3ccccc23)N(C1)C(=O)OCC1c2ccccc2-c2ccccc12 WFEHCHZUPYHPOT-IZLXSDGUSA-N 0.000 description 2
- GYRZGYYSKULJRU-OAHLLOKOSA-N 9H-fluoren-9-ylmethyl (2R)-2-formyl-4,4-dimethylpyrrolidine-1-carboxylate Chemical compound C(=O)[C@@H]1N(CC(C1)(C)C)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 GYRZGYYSKULJRU-OAHLLOKOSA-N 0.000 description 2
- JPIGUZUYIBLKEB-BXXZMZEQSA-N 9H-fluoren-9-ylmethyl (2S)-2-(5-bromo-8-hydroxy-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound BrC1=C2CCOC(C2=C(C=C1)O)[C@H]1N(CCC1)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 JPIGUZUYIBLKEB-BXXZMZEQSA-N 0.000 description 2
- QMMPTFILKKLIGO-RPLLCQBOSA-N 9H-fluoren-9-ylmethyl (2S)-2-[(1S)-8-hydroxy-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound OC=1C=CC=C2CCO[C@@H](C=12)[C@H]1N(CCC1)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 QMMPTFILKKLIGO-RPLLCQBOSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 206010001541 Akinesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MTBWTYMKTPCMRC-UHFFFAOYSA-N BrC1=C(CCO[Si](C)(C)C(C)(C)C)C=C(C=C1)F Chemical compound BrC1=C(CCO[Si](C)(C)C(C)(C)C)C=C(C=C1)F MTBWTYMKTPCMRC-UHFFFAOYSA-N 0.000 description 2
- 208000021465 Brief psychotic disease Diseases 0.000 description 2
- 208000011597 CGF1 Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000001573 Cataplexy Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 2
- 208000027691 Conduct disease Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 208000024254 Delusional disease Diseases 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010016845 Foetal alcohol syndrome Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 208000005793 Restless legs syndrome Diseases 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 208000019568 Shared Paranoid disease Diseases 0.000 description 2
- 208000028810 Shared psychotic disease Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DJIQDHXAMYMRRC-ZCFIWIBFSA-N [(2R)-4,4-dimethylpyrrolidin-2-yl]methanol Chemical compound CC1(C[C@@H](NC1)CO)C DJIQDHXAMYMRRC-ZCFIWIBFSA-N 0.000 description 2
- OIHLXXYXWMVNRS-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCCC1=C(C(=O)C2CN(C2)C(=O)OC(C)(C)C)C=CC=C1 Chemical compound [Si](C)(C)(C(C)(C)C)OCCC1=C(C(=O)C2CN(C2)C(=O)OC(C)(C)C)C=CC=C1 OIHLXXYXWMVNRS-UHFFFAOYSA-N 0.000 description 2
- XEJYYPFOQCCBLI-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCCC1=C(C=CC=C1)C(C1CN(C1)C(=O)OC(C)(C)C)O Chemical compound [Si](C)(C)(C(C)(C)C)OCCC1=C(C=CC=C1)C(C1CN(C1)C(=O)OC(C)(C)C)O XEJYYPFOQCCBLI-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000026345 acute stress disease Diseases 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 208000014679 binge eating disease Diseases 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960004205 carbidopa Drugs 0.000 description 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 2
- 229960004782 chlordiazepoxide Drugs 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 208000026725 cyclothymic disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 2
- 229960003337 entacapone Drugs 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 description 2
- 201000007794 fetal alcohol syndrome Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000000380 hallucinogen Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000001962 neuropharmacologic effect Effects 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- SYKXNRFLNZUGAJ-UHFFFAOYSA-N platinum;triphenylphosphane Chemical compound [Pt].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 SYKXNRFLNZUGAJ-UHFFFAOYSA-N 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical group 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000004039 social cognition Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 201000001716 specific phobia Diseases 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FZUZYZRHIRHACV-MRTLOADZSA-N tert-butyl (2R)-2-[4-fluoro-2-(oxan-2-yloxymethyl)benzoyl]pyrrolidine-1-carboxylate Chemical compound FC1=CC(=C(C(=O)[C@@H]2N(CCC2)C(=O)OC(C)(C)C)C=C1)COC1OCCCC1 FZUZYZRHIRHACV-MRTLOADZSA-N 0.000 description 2
- PZGJHPSEUOLITQ-VYRBHSGPSA-N tert-butyl (2S)-2-(3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C1OCCC2=C1C=CC=C2 PZGJHPSEUOLITQ-VYRBHSGPSA-N 0.000 description 2
- QFRGXWZSPIORMB-PCKAHOCUSA-N tert-butyl (2S)-2-(4-chloro-6-fluoro-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound ClC1COC(C2=CC=C(C=C12)F)[C@H]1N(CCC1)C(=O)OC(C)(C)C QFRGXWZSPIORMB-PCKAHOCUSA-N 0.000 description 2
- QVGAVLXCCDWKPH-LSLKUGRBSA-N tert-butyl (2S)-2-(5-fluoro-1,3-dihydro-2-benzofuran-1-yl)azetidine-1-carboxylate Chemical compound FC=1C=C2COC(C2=CC=1)[C@H]1N(CC1)C(=O)OC(C)(C)C QVGAVLXCCDWKPH-LSLKUGRBSA-N 0.000 description 2
- OUDZYDFNGROGHT-MLCCFXAWSA-N tert-butyl (2S)-2-(5-fluoro-1,3-dihydro-2-benzofuran-1-yl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C1OCc2cc(F)ccc12 OUDZYDFNGROGHT-MLCCFXAWSA-N 0.000 description 2
- FJTIVBNGXWNSKI-BHWOMJMDSA-N tert-butyl (2S)-2-(6-cyano-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound C(#N)C=1C=C2CCOC(C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C FJTIVBNGXWNSKI-BHWOMJMDSA-N 0.000 description 2
- IKUVYMKKSFQTPT-VYRBHSGPSA-N tert-butyl (2S)-2-(6-fluoro-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound FC=1C=C2CCOC(C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C IKUVYMKKSFQTPT-VYRBHSGPSA-N 0.000 description 2
- USORSNLZOJNIEQ-FHERZECASA-N tert-butyl (2S)-2-(6-fluoro-4-hydroxy-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound FC=1C=C2C(COC(C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C)O USORSNLZOJNIEQ-FHERZECASA-N 0.000 description 2
- AEDKBKUNNOTPPR-HKUYNNGSSA-N tert-butyl (2S)-2-[(1S)-6-(1,2-oxazol-5-yl)-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1[C@H]1OCCC2=C1C=CC(=C2)C1=CC=NO1 AEDKBKUNNOTPPR-HKUYNNGSSA-N 0.000 description 2
- KDEIYCOMRDXAAO-ROUUACIJSA-N tert-butyl (2S)-2-[(1S)-6-acetyl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound C(C)(=O)C=1C=C2CCO[C@@H](C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C KDEIYCOMRDXAAO-ROUUACIJSA-N 0.000 description 2
- SNBCFJJPECVJBS-SFTDATJTSA-N tert-butyl (2S)-2-[(1S)-6-pyridin-2-yl-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound N1=C(C=CC=C1)C=1C=C2CCO[C@@H](C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C SNBCFJJPECVJBS-SFTDATJTSA-N 0.000 description 2
- JVNXVYONBGMBRX-ZENAZSQFSA-N tert-butyl (2S)-2-[4-fluoro-2-(oxan-2-yloxymethyl)benzoyl]azetidine-1-carboxylate Chemical compound FC1=CC(=C(C(=O)[C@H]2N(CC2)C(=O)OC(C)(C)C)C=C1)COC1OCCCC1 JVNXVYONBGMBRX-ZENAZSQFSA-N 0.000 description 2
- WFVZVMGMPBTVBW-VYRBHSGPSA-N tert-butyl (2S)-2-[[4-fluoro-2-(2-hydroxyethyl)phenyl]-hydroxymethyl]pyrrolidine-1-carboxylate Chemical compound FC1=CC(=C(C=C1)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)O)CCO WFVZVMGMPBTVBW-VYRBHSGPSA-N 0.000 description 2
- GEZYSERUZLESAP-BHWOMJMDSA-N tert-butyl (2S)-2-[[5-fluoro-2-(3-hydroxypropyl)phenyl]-hydroxymethyl]pyrrolidine-1-carboxylate Chemical compound FC=1C=CC(=C(C=1)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)O)CCCO GEZYSERUZLESAP-BHWOMJMDSA-N 0.000 description 2
- KOGIRXZAGUVJGJ-SFVWDYPZSA-N tert-butyl (2S)-2-[hydroxy-[5-(hydroxymethyl)-1,3-benzodioxol-4-yl]methyl]pyrrolidine-1-carboxylate Chemical compound OC([C@H]1N(CCC1)C(=O)OC(C)(C)C)C1=C(C=CC=2OCOC=21)CO KOGIRXZAGUVJGJ-SFVWDYPZSA-N 0.000 description 2
- NNCPMJHKYIRKSA-SECBINFHSA-N tert-butyl (2r)-2-acetylpyrrolidine-1-carboxylate Chemical compound CC(=O)[C@H]1CCCN1C(=O)OC(C)(C)C NNCPMJHKYIRKSA-SECBINFHSA-N 0.000 description 2
- AYNAJTJLWNLXBC-QMMMGPOBSA-N tert-butyl (2s)-2-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate Chemical compound CON(C)C(=O)[C@@H]1CCN1C(=O)OC(C)(C)C AYNAJTJLWNLXBC-QMMMGPOBSA-N 0.000 description 2
- LVUWMMQELRNLJE-UHFFFAOYSA-N tert-butyl 3-[hydroxy-[2-(2-hydroxyethyl)phenyl]methyl]azetidine-1-carboxylate Chemical compound OC(C1CN(C1)C(=O)OC(C)(C)C)C1=C(C=CC=C1)CCO LVUWMMQELRNLJE-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229960003741 tranylcypromine Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- HIEVZUIEZJLCDT-JSGCOSHPSA-N (1R)-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromene-8-carbonitrile Chemical compound N1[C@@H](CCC1)[C@@H]1OCCC2=CC=CC(=C12)C#N HIEVZUIEZJLCDT-JSGCOSHPSA-N 0.000 description 1
- QUMBMLCQKHWSRP-IAMFDIQRSA-N (1R)-6-fluoro-1-[(2S)-pyrrolidin-2-yl]-3,4-dihydro-1H-isochromen-4-ol Chemical compound FC=1C=C2C(CO[C@H](C2=CC=1)[C@H]1NCCC1)O QUMBMLCQKHWSRP-IAMFDIQRSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- GBYODGYCWDHESM-UONOGXRCSA-N (2S)-2-[(1R)-6-fluoro-3,4-dihydro-1H-isochromen-1-yl]-1-methylpyrrolidine Chemical compound FC=1C=C2CCO[C@H](C2=CC=1)[C@H]1N(CCC1)C GBYODGYCWDHESM-UONOGXRCSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- CYNAPIVXKRLDER-LBPRGKRZSA-N (2s)-2-benzamido-3-(4-hydroxy-3-nitrophenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C([N+]([O-])=O)=C1 CYNAPIVXKRLDER-LBPRGKRZSA-N 0.000 description 1
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical compound O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- IBHYZKHFROARHA-UHFFFAOYSA-N 1-(2-bromo-5-fluorophenyl)ethanol Chemical compound CC(O)C1=CC(F)=CC=C1Br IBHYZKHFROARHA-UHFFFAOYSA-N 0.000 description 1
- XTDTYSBVMBQIBT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanol Chemical compound CC(O)C1=CC=C(Br)C=C1 XTDTYSBVMBQIBT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JADSGOFBFPTCHG-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)ethanol Chemical compound OCCC1=CC=C2OCOC2=C1 JADSGOFBFPTCHG-UHFFFAOYSA-N 0.000 description 1
- DZIAYQUNXYWRHS-UHFFFAOYSA-N 2-(2-bromo-6-fluorophenyl)ethanol Chemical compound OCCC1=C(F)C=CC=C1Br DZIAYQUNXYWRHS-UHFFFAOYSA-N 0.000 description 1
- FIYINHRBZIWYNZ-UHFFFAOYSA-N 2-(2-bromophenyl)-2,2-difluoroethanol Chemical compound BrC1=C(C=CC=C1)C(CO)(F)F FIYINHRBZIWYNZ-UHFFFAOYSA-N 0.000 description 1
- PMOSJSPFNDUAFY-UHFFFAOYSA-N 2-(4-bromophenyl)ethanol Chemical compound OCCC1=CC=C(Br)C=C1 PMOSJSPFNDUAFY-UHFFFAOYSA-N 0.000 description 1
- CZERVGSLFCZHHQ-UHFFFAOYSA-N 2-[(2-bromo-5-fluorophenyl)methylperoxy]oxane Chemical compound C1CCOC(C1)OOCC2=C(C=CC(=C2)F)Br CZERVGSLFCZHHQ-UHFFFAOYSA-N 0.000 description 1
- YJLFJEVJGKFDJE-UHFFFAOYSA-N 2-chloro-2-(3-fluorophenyl)ethanol Chemical compound ClC(CO)C1=CC(=CC=C1)F YJLFJEVJGKFDJE-UHFFFAOYSA-N 0.000 description 1
- XAEBTCPOZVEMHR-UHFFFAOYSA-N 2-methylpropan-2-ol;potassium Chemical compound [K].CC(C)(C)O XAEBTCPOZVEMHR-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- APTJYJKYTJBTMY-UHFFFAOYSA-N 3-(2-bromo-3-fluorophenyl)propan-1-ol Chemical compound OCCCC1=CC=CC(F)=C1Br APTJYJKYTJBTMY-UHFFFAOYSA-N 0.000 description 1
- ZBRYANYANGMGFY-UHFFFAOYSA-N 3-(6-fluoro-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine Chemical compound FC=1C=C2CCOC(C2=CC=1)C1CNCC1 ZBRYANYANGMGFY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CODFXJPNZHQAQN-UHFFFAOYSA-N 4-bromo-3-(2-hydroxyethyl)phenol Chemical compound OCCC1=CC(O)=CC=C1Br CODFXJPNZHQAQN-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
- 101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QMMPTFILKKLIGO-BXXZMZEQSA-N 9H-fluoren-9-ylmethyl (2S)-2-(8-hydroxy-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound OC=1C=CC=C2CCOC(C=12)[C@H]1N(CCC1)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 QMMPTFILKKLIGO-BXXZMZEQSA-N 0.000 description 1
- XWAXQOPFZBVRNG-IGKIAQTJSA-N 9H-fluoren-9-ylmethyl (2S)-2-[(1R)-8-(trifluoromethylsulfonyloxy)-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=CC2=C1[C@@H](OCC2)[C@@H]1CCCN1C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 XWAXQOPFZBVRNG-IGKIAQTJSA-N 0.000 description 1
- XWAXQOPFZBVRNG-RPLLCQBOSA-N 9H-fluoren-9-ylmethyl (2S)-2-[(1S)-8-(trifluoromethylsulfonyloxy)-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=CC2=C1[C@H](OCC2)[C@@H]1CCCN1C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 XWAXQOPFZBVRNG-RPLLCQBOSA-N 0.000 description 1
- LQVMZVKOVPITOO-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbonochloridate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)Cl)=CC=C2 LQVMZVKOVPITOO-UHFFFAOYSA-N 0.000 description 1
- NICPJLVQTQFOIN-AWEZNQCLSA-N 9h-fluoren-9-ylmethyl (2s)-2-formylpyrrolidine-1-carboxylate Chemical compound O=C[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 NICPJLVQTQFOIN-AWEZNQCLSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229940124810 Alzheimer's drug Drugs 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000035183 Benign hereditary chorea Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- SMASNJWITCAOHA-UHFFFAOYSA-N BrC1=C(CCO[Si](C)(C)C(C)(C)C)C=CC(=C1)C Chemical compound BrC1=C(CCO[Si](C)(C)C(C)(C)C)C=CC(=C1)C SMASNJWITCAOHA-UHFFFAOYSA-N 0.000 description 1
- 206010050012 Bradyphrenia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- CVKUMNRCIJMVAR-UHFFFAOYSA-N Fenoldopam mesylate Chemical compound CS(O)(=O)=O.C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 CVKUMNRCIJMVAR-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 208000014513 Hoarding disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022520 Intention tremor Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028403 Mutism Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100028646 Nociceptin receptor Human genes 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000012075 Paroxysmal dystonia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 206010073211 Postural tremor Diseases 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 1
- 208000028665 Reactive Attachment disease Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- 206010039917 Selective mutism Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- 208000011962 Substance-induced mood disease Diseases 0.000 description 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010064805 Tachyphrenia Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DJIQDHXAMYMRRC-LURJTMIESA-N [(2s)-4,4-dimethylpyrrolidin-2-yl]methanol Chemical compound CC1(C)CN[C@H](CO)C1 DJIQDHXAMYMRRC-LURJTMIESA-N 0.000 description 1
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
- JGNMDBSOEKSHPR-UHFFFAOYSA-N [ClH]1OC=C1 Chemical compound [ClH]1OC=C1 JGNMDBSOEKSHPR-UHFFFAOYSA-N 0.000 description 1
- XAIGSMBVLKSWME-BGERDNNASA-N [Si](C)(C)(C(C)(C)C)OCCC1=C(C=CC(=C1)F)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)O Chemical compound [Si](C)(C)(C(C)(C)C)OCCC1=C(C=CC(=C1)F)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)O XAIGSMBVLKSWME-BGERDNNASA-N 0.000 description 1
- MPRLWERBMJJRQV-HMTLIYDFSA-N [Si](C)(C)(C(C)(C)C)OCCCC1=C(C=C(C=C1)F)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)O Chemical compound [Si](C)(C)(C(C)(C)C)OCCCC1=C(C=C(C=C1)F)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)O MPRLWERBMJJRQV-HMTLIYDFSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000000063 antileukemic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- FJTKCFSPYUMXJB-UHFFFAOYSA-N bevantolol hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC[NH2+]CC(O)COC1=CC=CC(C)=C1 FJTKCFSPYUMXJB-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical class [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000003372 dissociative anesthetic agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000009985 drug-induced dyskinesia Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 229960004009 fenoldopam mesylate Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000002886 generalized dystonia Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001505 hypomanic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000015046 intermittent explosive disease Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 125000004250 isochroman-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])OC2([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 206010023461 kleptomania Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- AMVCFIFDMKEIRE-UHFFFAOYSA-N methyl 2-(2-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1Br AMVCFIFDMKEIRE-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000016334 muscle symptom Diseases 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- OYVXVLSZQHSNDK-UHFFFAOYSA-N n-methoxy-n-methylacetamide Chemical compound CON(C)C(C)=O OYVXVLSZQHSNDK-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 201000002274 psychologic vaginismus Diseases 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 201000004645 pyromania Diseases 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PCNRQYHSJVEIGH-ASTDGNLGSA-M sodium;5-benzo[e]benzotriazol-2-yl-2-[(e)-2-phenylethenyl]benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC(N2N=C3C4=CC=CC=C4C=CC3=N2)=CC=C1\C=C\C1=CC=CC=C1 PCNRQYHSJVEIGH-ASTDGNLGSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- GQWFOLRHEBJXRK-NNJIEVJOSA-N tert-butyl (2R)-2-(5-fluoro-1-methyl-3H-2-benzofuran-1-yl)pyrrolidine-1-carboxylate Chemical compound FC=1C=C2COC(C2=CC=1)(C)[C@@H]1N(CCC1)C(=O)OC(C)(C)C GQWFOLRHEBJXRK-NNJIEVJOSA-N 0.000 description 1
- GQWFOLRHEBJXRK-QAPCUYQASA-N tert-butyl (2R)-2-[(1S)-5-fluoro-1-methyl-3H-2-benzofuran-1-yl]pyrrolidine-1-carboxylate Chemical compound FC=1C=C2CO[C@](C2=CC=1)(C)[C@@H]1N(CCC1)C(=O)OC(C)(C)C GQWFOLRHEBJXRK-QAPCUYQASA-N 0.000 description 1
- BALAMPGMMHUJKU-LBAUFKAWSA-N tert-butyl (2S)-2-(8-fluoro-3,4-dihydro-1H-isochromen-1-yl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C1OCCC2=C1C(F)=CC=C2 BALAMPGMMHUJKU-LBAUFKAWSA-N 0.000 description 1
- GRMMTMMBTSTZOY-JKSUJKDBSA-N tert-butyl (2S)-2-[(1R)-6-bromo-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound BrC=1C=C2CCO[C@H](C2=CC=1)[C@H]1N(CCC1)C(=O)OC(C)(C)C GRMMTMMBTSTZOY-JKSUJKDBSA-N 0.000 description 1
- VKSFQWOAUCVMJT-ARBMLRGPSA-N tert-butyl (2S)-2-[(1S)-6-[(E)-3-(dimethylamino)prop-2-enoyl]-3,4-dihydro-1H-isochromen-1-yl]pyrrolidine-1-carboxylate Chemical compound CN(C)\C=C\C(=O)C1=CC2=C(C=C1)[C@H](OCC2)[C@@H]1CCCN1C(=O)OC(C)(C)C VKSFQWOAUCVMJT-ARBMLRGPSA-N 0.000 description 1
- LULASWZTZITFOK-LSLKUGRBSA-N tert-butyl (2S)-2-[[4-fluoro-2-(hydroxymethyl)phenyl]-hydroxymethyl]azetidine-1-carboxylate Chemical compound FC1=CC(=C(C=C1)C([C@H]1N(CC1)C(=O)OC(C)(C)C)O)CO LULASWZTZITFOK-LSLKUGRBSA-N 0.000 description 1
- RZXGKLUDDPTFII-MLCCFXAWSA-N tert-butyl (2S)-2-[[4-fluoro-2-(hydroxymethyl)phenyl]-hydroxymethyl]pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](CCC1)C(O)C1=C(C=C(C=C1)F)CO RZXGKLUDDPTFII-MLCCFXAWSA-N 0.000 description 1
- ABVHVQCTBAJTSP-VYRBHSGPSA-N tert-butyl (2S)-2-[[4-fluoro-2-(methylsulfonyloxymethyl)phenyl]-hydroxymethyl]pyrrolidine-1-carboxylate Chemical compound FC1=CC(=C(C=C1)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)O)COS(=O)(=O)C ABVHVQCTBAJTSP-VYRBHSGPSA-N 0.000 description 1
- HXGLTVHQMLKNPS-BHWOMJMDSA-N tert-butyl (2S)-2-[hydroxy-[2-(2-hydroxy-2-methylpropyl)phenyl]methyl]pyrrolidine-1-carboxylate Chemical compound OC([C@H]1N(CCC1)C(=O)OC(C)(C)C)C1=C(C=CC=C1)CC(C)(C)O HXGLTVHQMLKNPS-BHWOMJMDSA-N 0.000 description 1
- AYNAJTJLWNLXBC-MRVPVSSYSA-N tert-butyl (2r)-2-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate Chemical compound CON(C)C(=O)[C@H]1CCN1C(=O)OC(C)(C)C AYNAJTJLWNLXBC-MRVPVSSYSA-N 0.000 description 1
- KZNDGAGWQPGYTB-SECBINFHSA-N tert-butyl (2r)-2-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@@H]1C=O KZNDGAGWQPGYTB-SECBINFHSA-N 0.000 description 1
- NNCPMJHKYIRKSA-VIFPVBQESA-N tert-butyl (2s)-2-acetylpyrrolidine-1-carboxylate Chemical compound CC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C NNCPMJHKYIRKSA-VIFPVBQESA-N 0.000 description 1
- KZNDGAGWQPGYTB-VIFPVBQESA-N tert-butyl (2s)-2-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@H]1C=O KZNDGAGWQPGYTB-VIFPVBQESA-N 0.000 description 1
- AOVSULZRHILJIN-ZETCQYMHSA-N tert-butyl (2s)-4,4-difluoro-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(F)C[C@H]1C=O AOVSULZRHILJIN-ZETCQYMHSA-N 0.000 description 1
- MOLHQYMJBRBXAN-MRVPVSSYSA-N tert-butyl (3s)-3-formylmorpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC[C@H]1C=O MOLHQYMJBRBXAN-MRVPVSSYSA-N 0.000 description 1
- HLSMXLFZMJISCP-UHFFFAOYSA-N tert-butyl 3-(3,4-dihydro-1H-isochromen-1-yl)azetidine-1-carboxylate Chemical compound C1(OCCC2=CC=CC=C12)C1CN(C1)C(=O)OC(C)(C)C HLSMXLFZMJISCP-UHFFFAOYSA-N 0.000 description 1
- RPCWHOFDACENQM-UHFFFAOYSA-N tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate Chemical compound CON(C)C(=O)C1CN(C(=O)OC(C)(C)C)C1 RPCWHOFDACENQM-UHFFFAOYSA-N 0.000 description 1
- DWLADVOODHZCFV-UHFFFAOYSA-N tert-butyl 3-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)C1 DWLADVOODHZCFV-UHFFFAOYSA-N 0.000 description 1
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960003740 vilazodone Drugs 0.000 description 1
- UXDQRXUZPXSLJK-UHFFFAOYSA-N vilazodone Chemical compound C1=CC(C#N)=C[C]2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CN=C21 UXDQRXUZPXSLJK-UHFFFAOYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010607608.6A CN111925360B (zh) | 2015-02-11 | 2016-02-11 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 | |
| US62/115,064 | 2015-02-11 | ||
| CN202010607608.6A CN111925360B (zh) | 2015-02-11 | 2016-02-11 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
| PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
| CN201680018639.XA CN107531674B (zh) | 2015-02-11 | 2016-02-11 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680018639.XA Division CN107531674B (zh) | 2015-02-11 | 2016-02-11 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111925360A CN111925360A (zh) | 2020-11-13 |
| CN111925360B true CN111925360B (zh) | 2024-03-22 |
Family
ID=55456908
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010607608.6A Active CN111925360B (zh) | 2015-02-11 | 2016-02-11 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
| CN201680018639.XA Active CN107531674B (zh) | 2015-02-11 | 2016-02-11 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680018639.XA Active CN107531674B (zh) | 2015-02-11 | 2016-02-11 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (enExample) |
| EP (2) | EP4046995B1 (enExample) |
| JP (3) | JP6657241B2 (enExample) |
| KR (1) | KR102601972B1 (enExample) |
| CN (2) | CN111925360B (enExample) |
| AU (1) | AU2016219253C1 (enExample) |
| CA (1) | CA2976095C (enExample) |
| CY (1) | CY1125198T1 (enExample) |
| DK (1) | DK3256466T3 (enExample) |
| EA (1) | EA201791804A1 (enExample) |
| ES (2) | ES2911910T3 (enExample) |
| HU (1) | HUE058698T2 (enExample) |
| IL (1) | IL253914B (enExample) |
| MX (2) | MX392664B (enExample) |
| MY (1) | MY188160A (enExample) |
| NZ (1) | NZ735011A (enExample) |
| PH (1) | PH12017501422A1 (enExample) |
| PL (1) | PL3256466T3 (enExample) |
| PT (1) | PT3256466T (enExample) |
| SG (2) | SG10201806809QA (enExample) |
| UA (1) | UA122222C2 (enExample) |
| WO (1) | WO2016130796A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102623321B1 (ko) * | 2015-02-11 | 2024-01-09 | 선오비온 파마슈티컬스 인코포레이티드 | 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체 |
| CN111925360B (zh) * | 2015-02-11 | 2024-03-22 | 赛诺维信制药公司 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
| JP7187437B2 (ja) * | 2016-07-29 | 2022-12-12 | サノビオン ファーマシューティカルズ インク | 化合物および組成物ならびにそれらの使用 |
| EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
| EA202090180A1 (ru) | 2017-06-30 | 2020-05-26 | Чейс Терапьютикс Корпорейшн | Композиции nk1-антагониста и способы лечения депрессии |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20210139376A (ko) | 2019-03-14 | 2021-11-22 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물 |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| WO2014106238A1 (en) * | 2012-12-31 | 2014-07-03 | Fang, Qun, Kevin | Heterocyclic compounds and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| DE69912279T2 (de) | 1998-06-30 | 2004-07-29 | Eli Lilly And Co., Indianapolis | 5-ht1f agonisten |
| SE9902267D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| RU2004117211A (ru) * | 2001-11-08 | 2005-03-27 | Сепракор, Инк. (Us) | Способы лечения депресии и других рассстройств цнс с использованием энантиомерно обогащшенных десметил-и дидесметилметаболитов циталопрама |
| BRPI0515830A (pt) * | 2004-12-21 | 2008-08-05 | F Hoffmann La Roche | derivados de cromano e usos dos mesmos no tratamento de distúrbios do sistema nervoso central |
| BRPI0707258A2 (pt) * | 2005-01-27 | 2011-04-26 | Hoffmann La Roche | uso de 2-imidazóis para o tratamento de distúrbios de cns |
| PE20061297A1 (es) | 2005-04-22 | 2006-12-24 | Wyeth Corp | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| KR102074089B1 (ko) * | 2009-12-04 | 2020-02-05 | 선오비온 파마슈티컬스 인코포레이티드 | 다환형 화합물 및 이의 사용 방법 |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| CN111925360B (zh) * | 2015-02-11 | 2024-03-22 | 赛诺维信制药公司 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
-
2016
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh active Active
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en not_active Ceased
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active Active
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh active Active
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en not_active IP Right Cessation
- 2016-02-11 MX MX2020001157A patent/MX392664B/es unknown
- 2016-02-11 US US15/041,852 patent/US9856238B2/en active Active
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja not_active Expired - Fee Related
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en not_active Ceased
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en active Active
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja not_active Expired - Fee Related
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en not_active Abandoned
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
- 2022-05-20 CY CY20221100352T patent/CY1125198T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| WO2014106238A1 (en) * | 2012-12-31 | 2014-07-03 | Fang, Qun, Kevin | Heterocyclic compounds and methods of use thereof |
Non-Patent Citations (1)
| Title |
|---|
| Martial Toffano，et al..Asymmetric routes towards polyfunctionalized pyrrolidines: application to the synthesis of alkaloid analogues.《Tetrahedron: Asymmetry》.2003,第14卷3365-3370. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111925360B (zh) | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 | |
| CN111171047B (zh) | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物 | |
| TWI813673B (zh) | 抗增生化合物及其用途 | |
| CN111183138A (zh) | 异色满化合物以及用途 | |
| HK40042391A (en) | 1-heterocyclyl isochromanyl compounds and analogus for treating cns disorders | |
| HK40078692A (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| HK40078692B (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| EA046724B1 (ru) | Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс | |
| HK1241876B (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| HK1241876A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| BR112017017354B1 (pt) | Composto e seu uso, composição, processo para preparar um composto | |
| HK40078355A (en) | Antiproliferation compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40042391 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |